26/11/2015 14:08:36 Cookie Policy Free Membership Login

Alliance Pharma Share Chat - APH

Share Name Share Symbol Market Type Share ISIN Share Description
Alliance Pharma LSE:APH London Ordinary Share GB0031030819 ORD 1P
  Price Change Price Change % Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -5.75 -11.27% 45.25 44.50 46.00 46.50 44.13 45.00 561,703 13:45:39
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 43.5 10.2 3.2 14.3 119.55

Alliance Pharma Share Discussion Threads

Showing 1276 to 1299 of 1300 messages
Post New Message
Chat Pages: 52  51  50  49  48  47  46  45  44  43  42  41  >>
pimper, I agree to an extent in that they have successfully integrated a number of products over the years that were well-established in their fields, and that were (pretty much without exception) non-core and niche products to the companies who sold them. They typically weren't promoted and little effort was put into their marketing / development by their owners. This presented profitable opportunities for APH to increase sales. Now I don't know much about the Sinclair portfolio, but this strikes me as a hugely different deal to anything they've done before. I will do some more research before I comment more on the portfolio; I remember seeing that the average age of the products APH acquired was at least 30 years old; I get the feeling that it's very different to those products coming with Sinclair. Also you have to remember that APH is run by a very small team of 20-30 people in a little town called chippenham in wiltshire. Everything is outsourced. I wonder how they will handle the scaling up required with the doubling in size of their business? Like Ram mentioned, they have gone from a fairly attractive debt profile to something rather different; maybe in 18 months I'll be saying how well they've sweated their assets and got the debt right down, but for the moment the risk profile has increased significantly. Personally I sold out half of my holding at just over 59p as I thought the price was a little high, I will keep on holding to see what happens but certainly I'm more wary now.cisk
Fair enough Cisk, each to their own. I myself do not hold the institutions who hold APH in the regard you do, but I understand your general conclusion re some people's ability to "sell their mums" for a quick profit. I don't quite understand this point though: "Is there something I've missed that means Alliance will be able to make these products work and make far more money out of them than Sinclair has?" Isn't that precisely what APH are so good at, with a proven track record in precisely that? And this deal gives them a major foothold in the Continental European market.pimpernel4
Forgot to mention their post acquisition debt position. Net Debt / EBITDA = 3.7 Hmmm. Anything over 3 is a red flag.ramridge
Fair enough and good luck to you ramridge. There seems to have been plenty of appetite at 44p this morning at just a 10% premium to the placement price. The compelling thing about APH is its relatively small free float of shares. As we saw earlier in the year it does not take much to get it motoring and the majority of the new shares must surely now sit in hands that are in it for the mid to long term. Let's see what the end of year share price is.pimpernel4
On first reading, it looks too expensive. EBITDA multiple of 14.7, and PE of 26. Paid too much. This together with the deeply discounted placing means I am staying away. Synergies have to be a lot more than £5m to make this attractive. All IMO and DOYRramridge
Indeed Norbert, let this sink in and settle and the next 12 months will clearly be transformational. On the plus side of it not being offered to retail, this way the shares should sit in safe, tight hands.pimpernel4
A few negatives such as it not being offered to retail investors, it's extremely dilutive and at a discount but those points aside its clearly transformational and earnings accretive and I agree that clearly this is a game changer for the Group w.r.t scale and opportunities.I have a lot of faith in John Dawson and the board to do the right thing and look forward to remaining a long term shareholder.norbert colon
John Dawson, Chief Executive of Alliance, commented: "This Acquisition represents a very significant development for Alliance. On completion, Alliance will be a significantly larger business with synergies in existing markets. Having over half of our business outside of the UK, we will have a greater ability to compete for international deals and in-licensing opportunities." ------------ Transaction highlights: -- Alliance to acquire 27 products including five key growth brands (Kelo-Cote(TM) , Flammacerium(TM) , Aloclair(TM) , Kelo-stretch(TM) and Atopiclair(TM) ). The acquisition of these complementary assets will materially increase the scale of the business. -- The Acquisition will significantly increase the Company's footprint outside of the UK and will provide an enhanced platform for further corporate development. -- In the 12 months ended 30 June 2015, the Healthcare Products Business generated revenues of GBP43.3 million and EBITDA before exceptional items of GBP9.0 million. It is estimated that cost-saving synergies of approximately GBP5.0 million will be achievable from the 12 months ending 31 December 2016. ------- An outstanding deal, by the look of it. Clearly a lot of work over the past months behind the scenes to make this happen. Well done to the Board and Management.pimpernel4
The excellent cash flow from operations means that I am not at all concerned by their borrowings. In 2005 the figure was £24m (including the convertible loan stock, since repaid) against profits of £661k for 10 months. If they didn't buy any more products, the current borrowings would be repaid in 2/3 years. They also have unused facilities of about £20m. Of more concern to me is that there is the occasional problem with a supplier - like Sanofi/Immucyst - which dents both profits and my confidence in management. Nevertheless, I shall continue to hold with the possibility of selling some if the price moves usefully higher.123prezzie
Buster - correct. Thats a 25% (ish) reduction in their debt which is not to be sniffed at. Its just more good news IMO.norbert colon
The proceeds of the settlement agreement will be used to reduce Alliance's net bank debt. Which was a fairly hefty £26.5m two months ago.busterdog2
Agreed. I have been a LTH here. Alliance has the cash it needs to expand and is profitable. It appears to have a very competent BOD. Good point mazarin makes about it may take some time for Immucyst to re-establish itself. Does anyone here have any views on the PE of 17, going forward?2vdm
I have been waiting for this settlement for a very long time and note that when APH first announced its loss of production of Immucyst a few years ago the immediate effect on the share price was negatively significant. Clearly its position in the marketplace was taken over by competitors and it could well take time for APH to recover in that area. Fortunately APH's Board have introduced several other products in meantime and therein lies their strength. I think the real value of this compensation lies in what APH finally decides to do with the proceeds and I suspect they'll probably continue to do what they always have done to date, i.e. look for further 'value enhancing' and proven products to add to their divirgent portfolio of products.mazarin
Today's RNS supports pimpernels post above although the market's response is very muted. The receipt of £6.7m cash seems significant in relation to profits and market cap, whilst also adding to their acquisition firepower. Another plus is that "constrained supplies" of Immucyst will be back on the market at the end of the year.123prezzie
Good luck Rivaldo. All the best with future investments. The thing with Alliance is that you never know which new deals are round the corner - they certainly seem to have the support to expand, when they see an opportunity.pimpernel4
I've sold and taken profits. It's been a great run, but APH is now on quite a decent rating and I'm unsure how much if any upside there is. On the downside, APH have invested "significant pre-marketing costs" in the launch of Diclectin from next year. However, I've come across this rather controversial news from Canada, where Diclectin is charged with being no more and possibly less efficacious than other products - there's lots of other coverage on the web: Http://www.thestar.com/news/canada/2015/10/14/health-canada-hands-over-documents-but-muzzles-doctor.html Good luck all.rivaldo
there must be a big seller as there have been tens and tens of £thousands bought recently and the share price hasn't moved much.domple
£20,000 buy!!domple
Another decent purchase...mms playing games??domple
I spoke too soon about the rises!!domple
I am Busy day thoughpimpernel4
btw, is anyone else on this thread??lol would appreciate others' views!! Is this a good share??domple
Early rise..... up 0.5p on 5,000 purchase Should hopefully see some good movement if this continues....domple
strong finish to the daydomple
Chat Pages: 52  51  50  49  48  47  46  45  44  43  42  41  >>

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 151126 14:08